CHICAGO–(BUSINESS WIRE)–Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, today announced that the U.S. Food and Drug Administration (“FDA”) has approved a high-concentration formulation (“HCF”) for YUSIMRY® (adalimumab-aqvh), as an interchangeable biosimilar to Humira®. Emerge Bioscience Pte. Ltd. (“Emerge”) holds the